Across TCGA pan-cancer cohorts, ACP7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACP7 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ACP7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACP7 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, HNSC, and ACC are the cancer types where ACP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.335	0.925	<.001	36	view →
HNSC	DFS	Median	All	0.128	0.710	.001	24	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	II,III,IV	0.893	0.681	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ACP7 tumor-vs-normal RNA expression · all ACP7 data types